Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA
Portfolio Pulse from
Akeso, Inc. announced that its New Drug Application for gumokimab, a monoclonal antibody targeting IL-17 for treating moderate to severe psoriasis, has been accepted by China's NMPA. This enhances Akeso's product synergy in autoimmune diseases.
January 27, 2025 | 2:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akeso's NDA acceptance for gumokimab by the NMPA is a positive regulatory milestone, potentially enhancing its market position in autoimmune treatments.
The acceptance of the NDA by the NMPA is a significant regulatory milestone for Akeso, indicating progress in its drug development pipeline. This could lead to future revenue streams if the drug is approved and commercialized, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90